Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
6.78
+0.09 (1.35%)
At close: Jul 30, 2025, 4:00 PM
6.87
+0.09 (1.33%)
Pre-market: Jul 31, 2025, 8:50 AM EDT
Company Description
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies.
It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis.
The company was founded in 2018 is based in LA Palma, California.
Liminatus Pharma, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Chris Kim |
Contact Details
Address: 6 Centerpointe Drive, #625 La Palma, California 90623 United States | |
| Phone | 213 273 5453 |
| Website | liminatuspharma.com |
Stock Details
| Ticker Symbol | LIMN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001831874 |
| ISIN Number | US53271X1081 |
Key Executives
| Name | Position |
|---|---|
| Chris Kim J.D., L.L.M. | Chief Executive Officer, Treasurer and Secretary |